[News] Biomarkers for subtypes of pancreatic ductal adenocarcinoma

Patients with pancreatic ductal adenocarcinoma have a poor prognosis, and those with advanced disease do not survive longer than 12 months, even after cancer treatment. One reason therapy might fail to improve survival is that pancreatic ductal adenocarcinoma could comprise several subtypes of disease, each requiring different treatments. Now, findings from a study by Alexander Muckenhuber (Technical University Munich, Munich, Germany) and colleagues suggest that subtypes identified by immunohistochemistry-based expression of cytokeratin 81 (KRT81) and hepatocyte nuclear factor 1A (HNF1A) have different survival outcomes and responses to chemotherapy.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: News Source Type: research